“Global CAR-T Cell Therapy Market, By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Abecma (idecabtagene vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Others), By Company (2020), By Region, Forecast & Opportunities, 2026”, Global CAR-T cell therapy market is expected to reach USD6134.56 million by 2026 and to grow with a double digit CAGR of 33.11% over the forecast period.
Key factors fueling the growth of global CAR-T cell therapy market include rising prevalence of cancer around the globe and increasing need for breakthrough therapeutic solutions. There is an increasing number of patients who are showing response failure to alternative treatments. This factor is also expected to foster the growth of global CAR-T cell therapy market in the coming years. Moreover, rising R&D expenditure and boom in the field of immuno-oncology are some other factors propelling the growth of this market. Also, rising government initiatives for promoting research for cell therapy in cancer and improving health care infrastructure are supporting the growth of global CAR-T cell therapy market.
Additionally, increasing clinical trials and development of new and effective therapy options are driving the growth of this market. The effectiveness of CAR-T cell therapy in treating cancer is anticipated to present huge growth opportunities for pharmaceutical and biotech companies. However, the market might also face some restrains. The complicated manufacturing process of CAR-T cells and high cost of the treatment might hamper the market growth. Furthermore, side effects of CAR-T cell therapy may lead to neurological problems and cytokine release syndrome (CRS). This factor also might pose as a challenge for the growth of global CAR-T cell therapy market.
The global CAR-T cell therapy market is segmented based on product type, tumor type, indication, treatment type, targeted antigen, end user, company and region. Based on targeted antigen, the market can be segmented into CD 19, BCMA (B-Cell Maturation Antigen) and others. Among them, CD 19 antigen is expected to hold largest market share during the forecast period as more companies are able to get their CD 19 antigens approved and have them commercially available. However, B-Cell Maturation Antigen (BCMA) is anticipated to witness fastest CAGR through 2026 as they play a critical role in regulating B-cell proliferation and survival.
Based on end user, global CAR-T cell therapy market can be segmented into Hospitals, Speciality Clinics, Ambulatory Surgical Centres and others. Among them, Hospitals segment is expected to witness high growth during the forecast period due to increasing number of hospital establishments across the globe.
Major players operating in the global CAR-T cell therapy market are Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Co., Cellectis SA, Amgen Inc., Pfizer Inc., Merck & Co. Inc., Intellia Therapeutics Inc., Novartis AG, Poseida Therapeutics Inc., Johnson & Johnson SA, Allogene Therapeutics Inc., Autolus Therapeutics PLC, Humanigen Inc., Sangamo Therapeutics, Inc., among others. The companies are undergoing extensive research & development activities to launch new CAR-T cell therapies in the market.
“North America dominated the global CAR-T cell therapy market in 2020 and is expected to hold its dominance through 2026 owing to large patient pool suffering from cancer in countries such as United States and Canada. Also, rapid development and launch of new therapies for the treatment of cancer by leading companies is making the region a profitable market for manufactures. Following North America, Europe is anticipated to be the second most prominent market for CAR-T cell therapy due to extensive research for development of cancer therapies in the region,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Global CAR-T Cell Therapy Market, By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Abecma (idecabtagene vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Others), By Company (2020), By Region, Forecast & Opportunities, 2026” has evaluated the future growth potential of global CAR-T cell therapy market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global CAR-T cell therapy market.
Browse Related Reports:
Global Head and Neck Cancer Therapeutics Market By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others), By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer), By Route of Administration (Injectable, Oral), By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centres, Others), By Region, Competition Forecast & Opportunities, 2026
Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026
Global Bioinformatics Market By Product & Services (Knowledge Management Tools, Bioinformatic Platforms & Bioinformatic Services), By Applications (Microbial Genome, Gene Engineering, Drug Development, Personalized Medicine, Omics & Others), By Sectors (Forensic Biotechnology, Medical Biotechnology, Academics, Environmental Biotechnology, Animal Biotechnology & Agriculture Biotechnology), By Region, Competition, Forecast & Opportunities, 2024
About TechSci Research:
TechSci Research is a leading global market research firm publishing premium market research reports. Serving 700 global clients with more than 600 premium market research studies, TechSci Research is serving clients across 11 different industrial verticals. TechSci Research specializes in research-based consulting assignments in high growth and emerging markets, leading technologies and niche applications. Our workforce of more than 100 fulltime Analysts and Consultants employing innovative research solutions and tracking global and country specific high growth markets helps TechSci clients to lead rather than follow market trends.
Mr. Ken Mathews
708 Third Avenue,
New York – 10017
For More Market Research Blogs Visit: https://g-dil.com/